Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798325 | 0.78 | GAA (0.53) | GAAMAPTHTTGFERSMN1; SMN2 | |
| SCHEMBL6799649 | 0.78 | CCR3 (0.55) | GAAMAPTKMT2ATNKSPARP1 | |
| SCHEMBL29968547 | 0.78 | CCR3 (0.55) | GAAMAPTKMT2ATNKSPARP1 | |
| SCHEMBL6429862 | 0.77 | GAA (0.60) | GAAMAPTHTTGFERSMN1; SMN2 | |
| SCHEMBL6428994 | 0.77 | GAA (0.70) | GAAMAPTHTTGFERSMN1; SMN2 | |
| SCHEMBL5203581 | 0.72 | GAA (0.54) | GAAMEN1KMT2ATNKSPARP1 | |
| SCHEMBL5733660 | 0.72 | GAA (0.54) | GAAMEN1KMT2ANPC1TNKS | |
| SCHEMBL7617666 | 0.72 | MAPT (0.55) | GAAMAPTHTTGFERSMN1; SMN2 | |
| SCHEMBL5371447 | 0.72 | HDAC6 (0.55) | GAATNKSPARP1PARP14ACHE | |
| SCHEMBL7499616 | 0.72 | MAPT (0.47) | GAAMAPTHTTGFERSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242639-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-12-02 | — | — | US | claimed |
| WO-2004089901-A2 | PHOSPHOLIPASE C INHIBITORS FOR USE IN TREATING INFLAMMATORY DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-10-21 | — | — | WO | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | GAA 3085/4885MAPT 1043/4885HTT 2992/4885 |
| US-20040242639-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | GAA 1146/4885MAPT 4701/4885HTT 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.